Company (Symbol)# Type Of Financing Number Of Shares,
Units Or Warrants
Amount Raised (M) Investors; Placement Agents; Details (Date)@(M)

Acura Pharmaceuticals Inc. (OTC BB:ACUR) Private placementN/A$14.5 Acura raised $14.5M through an agreement with Vivo Ventures Fund VI LP, Vivo Ventures Fund VI Affiliates Fund LP, GCE Holdings LLC and certain individual investors (8/21)
Advanced Cell Technology Inc. (OTC BB: ACTC) Private placement of senior secured convertible debentures and warrants N/A$10Advanced Cell is raising $10M through the private financing (8/20)
Alseres Pharmaceuticals Inc. (ALSE) Private placement of a convertible promissory note N/A$10Alseres amended an agreement from May, allowing it to borrow up to $10M from Ingalls & Snyder Value Partners LP (8/14)
BioCryst Pharmaceuticals Inc. (BCRX) Private placement of common stock and warrants 8.3S and W$65.3BioCryst raised $65.3M in the placement of 8.3M shares of stock and warrants, priced at $7.80 per share, to existing investors, including funds managed by Baker Brothers Investments, Kleiner Perkins Caulfield & Byers, EHS Holdings, OrbiMed Advisors, Texas Pacific Group Ventures and Stephens Investment Management (8/6)
Callisto Pharmaceuticals Inc. (AMEX:KAL) Private placement of common stock and warrants 1.12S and 22.5W$11.2Callisto raised $11.2M in the placement, which was co-led by RAB Special Situations (Master) Fund Ltd. and Absolute Octane Master Fund Ltd. (8/7)
CeNeS Pharmaceuticals plc (UK; LSE:CEN) Private placement of of common stockN/A £6.1($12.1)CeNeS completed a $12.1M placement (8/22)**
Cortex Pharmaceuticals Inc. (AMEX:COR) Registered direct offering7.1S and W for 2.83S $14.2Cortex raised about $14.2M; JMP Securities acted as lead placement agent, and Rodman & Renshaw LLC served as co-placement agent (8/24)
Curis Inc. (CRIS)Private placement of stock and warrants N/A$13Curis raised $13M in a private placement of units each comprised of a common share and a warrant to purchase 0.35 additional common shares at $1.06375 per unit (8/6)
Emisphere Technologies Inc. (EMIS) Registered direct offering2S and W for 0.4S $7.57Emisphere raised about $7.57M, selling 2M common shares and warrants to purchase 400,000 shares, at $3.785 per unit; ThinkEquity Partners LLC is sole placement agent (8/17)
Encysive Pharmaceuticals Inc. (ENCY) Registered offering7.7S and W for 7.7 S $15Encysive raised $15M selling 7.7M shares and five-year warrants for about 7.7M shares at $1.95 each (8/21)
Isolagen Inc. (AMEX:ILE) Registered direct offering6.76S $13.8Isolagen raised $13.8M through the offering of 6.76M shares at $2.04 each (8/15)
Lev Pharmaceuticals Inc. (OTC BB: LEVP) Registered direct offering23.3U $35Lev raised $35M, selling 23.3M units priced at $1.50 each to a select group of institutional investors; each unit consists of one share of common stock and warrants to purchase an additional 0.2 shares of common stock with an exercise price of $1.86 per share (8/14)
Marshall Edwards Inc. (MSHL) Private placement of common stock5.46S and W for 2.2S $16.4Marshall Edwards raised $16.4M through the sale of about 5.46M common shares at $3 each and five-year warrants to purchase about 2.2M shares at $3.60 apiece (8/7)
Medicure Inc. (Canada; AMEX: MCU) Term sheet and private placement of stock and warrants 13.04S and W for 3.9S$40 Medicure received $25M in a deal with Manchester Securities Corp. to monetize a percentage of its current and potential future revenues; it also issued about 13.04M shares at $1.15 and warrants to buy about 3.9M shares; Leerink Swann, A.G. Edwards & Sons Inc., Merriman Curhan Ford & Co. and RBC Capital Markets Inc. served as financial advisors (8/21)
Nanogen Inc. (NGEN)Registered offering of senior convertible notes and warrants N/A$20Nanogen raised $20M through the financing; Seven Hills Partners LLC served as the placement agent (8/27)
NPS Pharmaceuticals Inc. (NPSP) Private placement of Series B stock, Sensipar royalty-backed notes and convertible notes N/A$150NPS raised $150M by issuing $50M in convertible notes to funds managed by Visium Asset Management LLC, and $100M in Series B, Sensipar royalty-backed notes (8/8)
Nventa Bio-

pharmaceuticals Corp. (TSX:NVN)


placement of units

68.9U C$8.6


Nventa raised $8.15M selling 68.9M units, each

consisting of one common share and half a warrant (8/27)

Oculus Innovative Sciences Inc. (OCLS) Private placement of common stock1.3S and W for 0.4S $10.1Oculus raised $10.1M in a placement of 1.3M shares priced at $8 each and warrants to purchase up to 417,000 additional shares at an exercise price of $9.50 each (8/8)
Oragenics Inc. (AMEX:ONI) Private placement of common stock and warrants 4.6S and 4.6W$1.2Oragenics raised $1.2M in an equity-based financing with a group of investors (8/8)
Oramed Pharmaceuticals Inc. (Israel;OTC BB:ORMP) Private placement of stock and warrantsN/A $2Oramed raised $2M pricing shares at 50 cents each and warrants at 75 cents each (8/6)
Oxis International Inc. (OTC BB:OXIS) InvestmentN/A$0.5 Oxis received a $500,000 investment from Synvista Therapeutics Inc. (formerly Alteon Inc.) as part of a license agreement for BXT-51072 (8/22)
Peplin Ltd.

(Australia; ASX:PEP)



N/A A$20


Peplin raised $16.9M in a private placement (8/10)
Senesco Technologies Inc. (AMEX:SNT) Private placement of convertible debentures N/A$5Senesco raised $5M in three-year, secured convertible debentures with an 8% coupon (8/8)
SyntheMed Inc. (OTC BB:SYMD) Private placement of common stock2.8S $2.8SyntheMed raised $2.8M through the sale of 2.8M shares at $1 each; it also authorized the sale of an additional 3.2M shares on the same terms (8/14)
Urigen Pharmaceuticals Inc. (OTC BB:URGP) Private placementN/A$2.1 Urigen raised $2.1M in a financing led by Platinum-Montaur Life Sciences LLC (8/6)
Vermillion Inc. (formerly Ciphergen Biosystems Inc.; VRML) Private placement of common stock and warrants 24.4S and W for 19.5S$20.5 Vermillion raised $20.5M selling 24.4M shares and warrants to purchase an additional 19.5M shares priced at 92.5 cents apiece (8/24)
Vyteris Inc. (OTC BB:VYHN) Private placement of common stockN/A $12.7Vyteris raised $12.7M through the placement (8/1)

This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Funds from loan facilities are included only when the company takes a draw, if announced.

# Unless otherwise indicated, shares are traded on the Nasdaq exchange

@ Refers to the date of the press release.

** Denotes the date the item ran in BioWorld International.

Currency conversions are based on exchange rates at the time of the deal.

N/A = Not applicable; ND = Not disclosed.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange.

No Comments